Inhibition of Multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

Inhibition of Multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30-40% response rate, many fall into the range of 10-20%, with delivery across the blood brain barrie...

Full description

Bibliographic Details
Main Authors: Amanda eTivnan, Zaitun eZakaria, Caitrin eO'Leary, Donat eKogel, Jenny L Pokorny, Jann N Sarkaria, Jochen H M Prehn
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-06-01
Series:Frontiers in Neuroscience
Subjects:
Glioblastoma
siRNA
chemoresistance
Multidrug resistance protein 1
ABCC1
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00218/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00218/full

Similar Items